Vol. 21, Issue 1, 2021November 18, 2021 CDT
ccby-4.0
Second Thoughts on FDA’S COVID-Era Mental Health App Policy
Second Thoughts on FDA’S COVID-Era Mental Health App Policy
mental health appUS Food and Drug Administrationdigital therapeuticsFDAFDA enforcementmental healthpandemicanxiety disorder
Articles in Vol. 21, Issue 1, 2021
Vol. 21, Issue 1, 2021
- 8th Annual Symposium: Redefining & Regulating Health DataLeah Fowler
- Second Thoughts on FDA’S COVID-Era Mental Health App PolicyMichael Mattioli
- Location as HealthAnya E. R. Prince
- Health-Based Proxy Discrimination, Artificial Intelligence, and Big DataDaniel Schwarcz
- AI's Legitimate Interest: Towards a Public Benefit Privacy ModelCharlotte Tschider
- The Future of Stem Cell Therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health LensLeah Nadel
- Pandemic Policy: Protecting the Public Health of the United States by Federally Criminalizing the Wrongful Transmission of Foreign Infectious DiseaseLizzie Hardage
Michael Mattioli, Second Thoughts on FDA’S COVID-Era Mental Health App Policy, 21 HOUS. J. HEALTH L. & POL’Y 9 (2021).